nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—Blood creatinine increased—Pemetrexed—lung cancer	0.0148	0.0185	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Crizotinib—lung cancer	0.0118	0.0147	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Gefitinib—lung cancer	0.0107	0.0134	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—PXN—lung cancer	0.0104	0.0605	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Gefitinib—lung cancer	0.00986	0.0123	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Cisplatin—lung cancer	0.00903	0.0113	CcSEcCtD
Azilsartan medoxomil—Telmisartan—ABCG2—lung cancer	0.00897	0.321	CrCbGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Crizotinib—lung cancer	0.00881	0.011	CcSEcCtD
Azilsartan medoxomil—Angioedema—Gefitinib—lung cancer	0.00864	0.0108	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Cisplatin—lung cancer	0.00853	0.0107	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Crizotinib—lung cancer	0.00834	0.0104	CcSEcCtD
Azilsartan medoxomil—Losartan—UGT1A1—lung cancer	0.00829	0.296	CrCbGaD
Azilsartan medoxomil—Hyperuricaemia—Etoposide—lung cancer	0.00827	0.0103	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Crizotinib—lung cancer	0.00826	0.0103	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Pemetrexed—lung cancer	0.00805	0.0101	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Gefitinib—lung cancer	0.008	0.00999	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Etoposide—lung cancer	0.00781	0.00976	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PXN—lung cancer	0.00779	0.0455	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Pemetrexed—lung cancer	0.00762	0.00952	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Vinorelbine—lung cancer	0.00761	0.0095	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Gefitinib—lung cancer	0.00757	0.00946	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Pemetrexed—lung cancer	0.00755	0.00943	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Gefitinib—lung cancer	0.0075	0.00937	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Crizotinib—lung cancer	0.00734	0.00917	CcSEcCtD
Azilsartan medoxomil—Fatigue—Crizotinib—lung cancer	0.00733	0.00916	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Pemetrexed—lung cancer	0.00671	0.00838	CcSEcCtD
Azilsartan medoxomil—Fatigue—Pemetrexed—lung cancer	0.0067	0.00837	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Gefitinib—lung cancer	0.00667	0.00833	CcSEcCtD
Azilsartan medoxomil—Fatigue—Gefitinib—lung cancer	0.00666	0.00831	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Erlotinib—lung cancer	0.00638	0.00797	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Irinotecan—lung cancer	0.00627	0.00784	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Gemcitabine—lung cancer	0.00611	0.00763	CcSEcCtD
Azilsartan medoxomil—Asthenia—Crizotinib—lung cancer	0.0061	0.00762	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Topotecan—lung cancer	0.00596	0.00744	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Crizotinib—lung cancer	0.00582	0.00727	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Cisplatin—lung cancer	0.0057	0.00711	CcSEcCtD
Azilsartan medoxomil—Dizziness—Crizotinib—lung cancer	0.00562	0.00702	CcSEcCtD
Azilsartan medoxomil—Asthenia—Pemetrexed—lung cancer	0.00558	0.00696	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—OXTR—lung cancer	0.00557	0.0325	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Gefitinib—lung cancer	0.00554	0.00692	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Vinorelbine—lung cancer	0.00552	0.00689	CcSEcCtD
Azilsartan medoxomil—Pruritus—Pemetrexed—lung cancer	0.0055	0.00687	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Topotecan—lung cancer	0.0055	0.00686	CcSEcCtD
Azilsartan medoxomil—Pruritus—Gefitinib—lung cancer	0.00546	0.00682	CcSEcCtD
Azilsartan medoxomil—Rash—Crizotinib—lung cancer	0.00536	0.0067	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Crizotinib—lung cancer	0.00536	0.00669	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Pemetrexed—lung cancer	0.00532	0.00664	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Gefitinib—lung cancer	0.00528	0.0066	CcSEcCtD
Azilsartan medoxomil—Angioedema—Topotecan—lung cancer	0.00522	0.00652	CcSEcCtD
Azilsartan medoxomil—Dizziness—Pemetrexed—lung cancer	0.00514	0.00642	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Paclitaxel—lung cancer	0.00512	0.00639	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Vinorelbine—lung cancer	0.0051	0.00637	CcSEcCtD
Azilsartan medoxomil—Nausea—Crizotinib—lung cancer	0.00505	0.00631	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Methotrexate—lung cancer	0.00495	0.00619	CcSEcCtD
Azilsartan medoxomil—Rash—Pemetrexed—lung cancer	0.0049	0.00612	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Pemetrexed—lung cancer	0.0049	0.00611	CcSEcCtD
Azilsartan medoxomil—Rash—Gefitinib—lung cancer	0.00487	0.00608	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Gefitinib—lung cancer	0.00486	0.00607	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.00483	0.00604	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.00478	0.00597	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Methotrexate—lung cancer	0.00468	0.00585	CcSEcCtD
Azilsartan medoxomil—Nausea—Pemetrexed—lung cancer	0.00462	0.00576	CcSEcCtD
Azilsartan medoxomil—Nausea—Gefitinib—lung cancer	0.00459	0.00573	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Topotecan—lung cancer	0.00458	0.00571	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Irinotecan—lung cancer	0.00455	0.00569	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Topotecan—lung cancer	0.00453	0.00566	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Erlotinib—lung cancer	0.00453	0.00565	CcSEcCtD
Azilsartan medoxomil—Asthenia—Teniposide—lung cancer	0.00452	0.00564	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Erlotinib—lung cancer	0.00448	0.0056	CcSEcCtD
Azilsartan medoxomil—Angioedema—Vinorelbine—lung cancer	0.00447	0.00558	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—ITGB1—lung cancer	0.00447	0.0261	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Teniposide—lung cancer	0.00445	0.00556	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Gemcitabine—lung cancer	0.00445	0.00555	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Gemcitabine—lung cancer	0.00443	0.00554	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Teniposide—lung cancer	0.00431	0.00538	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Doxorubicin—lung cancer	0.00429	0.00536	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ITGB1—lung cancer	0.00425	0.0248	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Irinotecan—lung cancer	0.0042	0.00525	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00413	0.00516	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Cisplatin—lung cancer	0.00413	0.00516	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Gemcitabine—lung cancer	0.00409	0.00511	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—MET—lung cancer	0.00408	0.0238	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Doxorubicin—lung cancer	0.00405	0.00506	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Topotecan—lung cancer	0.00403	0.00503	CcSEcCtD
Azilsartan medoxomil—Fatigue—Topotecan—lung cancer	0.00402	0.00502	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Erlotinib—lung cancer	0.00398	0.00498	CcSEcCtD
Azilsartan medoxomil—Fatigue—Erlotinib—lung cancer	0.00398	0.00497	CcSEcCtD
Azilsartan medoxomil—Rash—Teniposide—lung cancer	0.00397	0.00496	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Teniposide—lung cancer	0.00396	0.00495	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Vinorelbine—lung cancer	0.00391	0.00489	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Irinotecan—lung cancer	0.00388	0.00484	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Vinorelbine—lung cancer	0.00388	0.00484	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGF—lung cancer	0.0038	0.0222	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Teniposide—lung cancer	0.00374	0.00467	CcSEcCtD
Azilsartan medoxomil—Telmisartan—ABCB1—lung cancer	0.00373	0.133	CrCbGaD
Azilsartan medoxomil—Oedema peripheral—Paclitaxel—lung cancer	0.00372	0.00465	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Paclitaxel—lung cancer	0.00371	0.00464	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Cisplatin—lung cancer	0.00352	0.0044	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Etoposide—lung cancer	0.0035	0.00437	CcSEcCtD
Azilsartan medoxomil—Asthenia—Vinblastine—lung cancer	0.00345	0.0043	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00345	0.0043	CcSEcCtD
Azilsartan medoxomil—Fatigue—Vinorelbine—lung cancer	0.00344	0.0043	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Paclitaxel—lung cancer	0.00343	0.00428	CcSEcCtD
Azilsartan medoxomil—Asthenia—Topotecan—lung cancer	0.00335	0.00418	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.00332	0.00415	CcSEcCtD
Azilsartan medoxomil—Asthenia—Erlotinib—lung cancer	0.00331	0.00414	CcSEcCtD
Azilsartan medoxomil—Pruritus—Topotecan—lung cancer	0.0033	0.00412	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Vinblastine—lung cancer	0.00329	0.0041	CcSEcCtD
Azilsartan medoxomil—Pruritus—Erlotinib—lung cancer	0.00327	0.00408	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Irinotecan—lung cancer	0.00323	0.00403	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Etoposide—lung cancer	0.00323	0.00403	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Topotecan—lung cancer	0.00319	0.00399	CcSEcCtD
Azilsartan medoxomil—Dizziness—Vinblastine—lung cancer	0.00318	0.00397	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Paclitaxel—lung cancer	0.00316	0.00395	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Erlotinib—lung cancer	0.00316	0.00394	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Docetaxel—lung cancer	0.00315	0.00394	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Docetaxel—lung cancer	0.00315	0.00393	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Gemcitabine—lung cancer	0.00314	0.00393	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Gemcitabine—lung cancer	0.00311	0.00389	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.0031	0.00387	CcSEcCtD
Azilsartan medoxomil—Dizziness—Topotecan—lung cancer	0.00309	0.00385	CcSEcCtD
Azilsartan medoxomil—Dizziness—Erlotinib—lung cancer	0.00305	0.00381	CcSEcCtD
Azilsartan medoxomil—Candesartan—ABCB1—lung cancer	0.00301	0.108	CrCbGaD
Azilsartan medoxomil—Angioedema—Paclitaxel—lung cancer	0.00301	0.00375	CcSEcCtD
Azilsartan medoxomil—Rash—Topotecan—lung cancer	0.00294	0.00367	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Topotecan—lung cancer	0.00294	0.00367	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Cisplatin—lung cancer	0.00293	0.00366	CcSEcCtD
Azilsartan medoxomil—Rash—Erlotinib—lung cancer	0.00291	0.00363	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Erlotinib—lung cancer	0.00291	0.00363	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Docetaxel—lung cancer	0.00291	0.00363	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Cisplatin—lung cancer	0.0029	0.00363	CcSEcCtD
Azilsartan medoxomil—Asthenia—Vinorelbine—lung cancer	0.00286	0.00358	CcSEcCtD
Azilsartan medoxomil—Nausea—Vinblastine—lung cancer	0.00285	0.00356	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Irinotecan—lung cancer	0.00284	0.00355	CcSEcCtD
Azilsartan medoxomil—Fatigue—Irinotecan—lung cancer	0.00284	0.00354	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.00284	0.00354	CcSEcCtD
Azilsartan medoxomil—Pruritus—Vinorelbine—lung cancer	0.00282	0.00353	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—CDH1—lung cancer	0.00279	0.0163	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.00278	0.00347	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—ABCB1—lung cancer	0.00278	0.0162	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Topotecan—lung cancer	0.00277	0.00346	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00277	0.00346	CcSEcCtD
Azilsartan medoxomil—Fatigue—Gemcitabine—lung cancer	0.00276	0.00345	CcSEcCtD
Azilsartan medoxomil—Nausea—Erlotinib—lung cancer	0.00274	0.00342	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Vinorelbine—lung cancer	0.00273	0.00341	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Doxorubicin—lung cancer	0.00271	0.00338	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—lung cancer	0.0027	0.0157	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Docetaxel—lung cancer	0.00268	0.00335	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Etoposide—lung cancer	0.00266	0.00332	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GRP—lung cancer	0.00265	0.0155	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—OXTR—lung cancer	0.00265	0.0155	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Vinorelbine—lung cancer	0.00264	0.0033	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Paclitaxel—lung cancer	0.00263	0.00329	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—GRP—lung cancer	0.00262	0.0153	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—OXTR—lung cancer	0.00262	0.0153	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Paclitaxel—lung cancer	0.00261	0.00326	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Cisplatin—lung cancer	0.00258	0.00322	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—lung cancer	0.00256	0.0149	CbGpPWpGaD
Azilsartan medoxomil—Rash—Vinorelbine—lung cancer	0.00252	0.00314	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Vinorelbine—lung cancer	0.00251	0.00314	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—FASLG—lung cancer	0.00251	0.0146	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GNG11—lung cancer	0.00248	0.0145	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—lung cancer	0.00237	0.0139	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—OXTR—lung cancer	0.00237	0.0139	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Vinorelbine—lung cancer	0.00237	0.00296	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Etoposide—lung cancer	0.00236	0.00295	CcSEcCtD
Azilsartan medoxomil—Asthenia—Irinotecan—lung cancer	0.00236	0.00295	CcSEcCtD
Azilsartan medoxomil—Fatigue—Etoposide—lung cancer	0.00236	0.00295	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—SRC—lung cancer	0.00236	0.0138	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.00236	0.00294	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Paclitaxel—lung cancer	0.00232	0.00289	CcSEcCtD
Azilsartan medoxomil—Fatigue—Paclitaxel—lung cancer	0.00231	0.00289	CcSEcCtD
Azilsartan medoxomil—Asthenia—Gemcitabine—lung cancer	0.0023	0.00287	CcSEcCtD
Azilsartan medoxomil—Pruritus—Gemcitabine—lung cancer	0.00227	0.00283	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Irinotecan—lung cancer	0.00225	0.00281	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Docetaxel—lung cancer	0.00223	0.00279	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG11—lung cancer	0.00222	0.013	CbGpPWpGaD
Azilsartan medoxomil—Skin disorder—Docetaxel—lung cancer	0.00221	0.00276	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Gemcitabine—lung cancer	0.00219	0.00274	CcSEcCtD
Azilsartan medoxomil—Dizziness—Irinotecan—lung cancer	0.00218	0.00272	CcSEcCtD
Azilsartan medoxomil—Asthenia—Cisplatin—lung cancer	0.00214	0.00268	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Methotrexate—lung cancer	0.00209	0.00262	CcSEcCtD
Azilsartan medoxomil—Rash—Irinotecan—lung cancer	0.00208	0.00259	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Irinotecan—lung cancer	0.00207	0.00259	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGFR—lung cancer	0.00207	0.0121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—OXTR—lung cancer	0.00205	0.012	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Cisplatin—lung cancer	0.00204	0.00255	CcSEcCtD
Azilsartan medoxomil—Losartan—ALB—lung cancer	0.00203	0.0726	CrCbGaD
Azilsartan medoxomil—Rash—Gemcitabine—lung cancer	0.00202	0.00252	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Gemcitabine—lung cancer	0.00202	0.00252	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Doxorubicin—lung cancer	0.00197	0.00246	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Docetaxel—lung cancer	0.00196	0.00245	CcSEcCtD
Azilsartan medoxomil—Asthenia—Etoposide—lung cancer	0.00196	0.00245	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Doxorubicin—lung cancer	0.00196	0.00245	CcSEcCtD
Azilsartan medoxomil—Fatigue—Docetaxel—lung cancer	0.00196	0.00245	CcSEcCtD
Azilsartan medoxomil—Nausea—Irinotecan—lung cancer	0.00196	0.00244	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—ANXA1—lung cancer	0.00195	0.0114	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ABCB1—lung cancer	0.00194	0.0693	CrCbGaD
Azilsartan medoxomil—Pruritus—Etoposide—lung cancer	0.00194	0.00242	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—ANXA1—lung cancer	0.00193	0.0113	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Paclitaxel—lung cancer	0.00193	0.00241	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—lung cancer	0.00192	0.0112	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GIPR—lung cancer	0.00191	0.0112	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Gemcitabine—lung cancer	0.0019	0.00238	CcSEcCtD
Azilsartan medoxomil—Pruritus—Paclitaxel—lung cancer	0.0019	0.00237	CcSEcCtD
Azilsartan medoxomil—Rash—Cisplatin—lung cancer	0.00188	0.00235	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Cisplatin—lung cancer	0.00188	0.00235	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Etoposide—lung cancer	0.00187	0.00234	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP8—lung cancer	0.00187	0.0109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—APP—lung cancer	0.00185	0.0108	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Paclitaxel—lung cancer	0.00184	0.00229	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—APP—lung cancer	0.00183	0.0107	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Doxorubicin—lung cancer	0.00181	0.00226	CcSEcCtD
Azilsartan medoxomil—Dizziness—Etoposide—lung cancer	0.00181	0.00226	CcSEcCtD
Azilsartan medoxomil—Dizziness—Paclitaxel—lung cancer	0.00178	0.00222	CcSEcCtD
Azilsartan medoxomil—Nausea—Cisplatin—lung cancer	0.00178	0.00222	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.00176	0.0103	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.00176	0.0103	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—lung cancer	0.00175	0.0102	CbGpPWpGaD
Azilsartan medoxomil—Rash—Etoposide—lung cancer	0.00173	0.00216	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Etoposide—lung cancer	0.00172	0.00215	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.0017	0.00212	CcSEcCtD
Azilsartan medoxomil—Rash—Paclitaxel—lung cancer	0.00169	0.00211	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Paclitaxel—lung cancer	0.00169	0.00211	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Doxorubicin—lung cancer	0.00167	0.00209	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—APP—lung cancer	0.00166	0.00966	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK3—lung cancer	0.00163	0.00954	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Docetaxel—lung cancer	0.00163	0.00204	CcSEcCtD
Azilsartan medoxomil—Nausea—Etoposide—lung cancer	0.00163	0.00203	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GRM8—lung cancer	0.00163	0.00949	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Docetaxel—lung cancer	0.00161	0.00201	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Methotrexate—lung cancer	0.00161	0.00201	CcSEcCtD
Azilsartan medoxomil—Nausea—Paclitaxel—lung cancer	0.00159	0.00199	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methotrexate—lung cancer	0.00159	0.00199	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Docetaxel—lung cancer	0.00156	0.00194	CcSEcCtD
Azilsartan medoxomil—Dizziness—Docetaxel—lung cancer	0.0015	0.00188	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—lung cancer	0.00147	0.00861	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.00147	0.00184	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—AVP—lung cancer	0.00144	0.0084	CbGpPWpGaD
Azilsartan medoxomil—Rash—Docetaxel—lung cancer	0.00143	0.00179	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Docetaxel—lung cancer	0.00143	0.00179	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—AVP—lung cancer	0.00142	0.0083	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Methotrexate—lung cancer	0.00142	0.00177	CcSEcCtD
Azilsartan medoxomil—Fatigue—Methotrexate—lung cancer	0.00141	0.00177	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP3—lung cancer	0.00141	0.00824	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2—lung cancer	0.00141	0.00823	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Doxorubicin—lung cancer	0.00139	0.00174	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Doxorubicin—lung cancer	0.00138	0.00172	CcSEcCtD
Azilsartan medoxomil—Nausea—Docetaxel—lung cancer	0.00135	0.00169	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—lung cancer	0.00135	0.00787	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GRP—lung cancer	0.00134	0.00781	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—OXTR—lung cancer	0.00134	0.00781	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.00129	0.00755	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—lung cancer	0.00129	0.00752	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GNG11—lung cancer	0.00125	0.00731	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.00123	0.00716	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Doxorubicin—lung cancer	0.00123	0.00153	CcSEcCtD
Azilsartan medoxomil—Fatigue—Doxorubicin—lung cancer	0.00122	0.00153	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—lung cancer	0.0012	0.00699	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Methotrexate—lung cancer	0.00118	0.00147	CcSEcCtD
Azilsartan medoxomil—Pruritus—Methotrexate—lung cancer	0.00116	0.00145	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Methotrexate—lung cancer	0.00112	0.0014	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—lung cancer	0.0011	0.00643	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Methotrexate—lung cancer	0.00108	0.00135	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GIPR—lung cancer	0.00108	0.00631	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTHLH—lung cancer	0.00105	0.00611	CbGpPWpGaD
Azilsartan medoxomil—Rash—Methotrexate—lung cancer	0.00103	0.00129	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methotrexate—lung cancer	0.00103	0.00129	CcSEcCtD
Azilsartan medoxomil—Asthenia—Doxorubicin—lung cancer	0.00102	0.00127	CcSEcCtD
Azilsartan medoxomil—Pruritus—Doxorubicin—lung cancer	0.001	0.00125	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ANXA1—lung cancer	0.000985	0.00575	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GIPR—lung cancer	0.000981	0.00573	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Methotrexate—lung cancer	0.000974	0.00122	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Doxorubicin—lung cancer	0.000972	0.00121	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000954	0.00557	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—POMC—lung cancer	0.000945	0.00551	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Doxorubicin—lung cancer	0.000939	0.00117	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—APP—lung cancer	0.000934	0.00545	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRM8—lung cancer	0.000919	0.00536	CbGpPWpGaD
Azilsartan medoxomil—Rash—Doxorubicin—lung cancer	0.000895	0.00112	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Doxorubicin—lung cancer	0.000895	0.00112	CcSEcCtD
Azilsartan medoxomil—Nausea—Doxorubicin—lung cancer	0.000843	0.00105	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—lung cancer	0.000835	0.00487	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRM8—lung cancer	0.000834	0.00487	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—lung cancer	0.000796	0.00464	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AXL—lung cancer	0.000765	0.00446	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—OXTR—lung cancer	0.000757	0.00442	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRP—lung cancer	0.000757	0.00442	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—lung cancer	0.000731	0.00427	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—AVP—lung cancer	0.000726	0.00424	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GNG11—lung cancer	0.000708	0.00413	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—lung cancer	0.000706	0.00412	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—OXTR—lung cancer	0.000687	0.00401	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRP—lung cancer	0.000687	0.00401	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GNG11—lung cancer	0.000643	0.00375	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADCY1—lung cancer	0.000637	0.00372	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000634	0.0037	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—COL4A2—lung cancer	0.000595	0.00347	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTHLH—lung cancer	0.000592	0.00346	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GIPR—lung cancer	0.00058	0.00338	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADCY1—lung cancer	0.000578	0.00338	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PPP2R1B—lung cancer	0.000564	0.00329	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ANXA1—lung cancer	0.000557	0.00325	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SDC4—lung cancer	0.000541	0.00316	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTHLH—lung cancer	0.000538	0.00314	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—lung cancer	0.000531	0.0031	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DUSP3—lung cancer	0.00053	0.00309	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—APP—lung cancer	0.000528	0.00308	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RHEB—lung cancer	0.00052	0.00303	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—lung cancer	0.000509	0.00297	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ANXA1—lung cancer	0.000505	0.00295	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRM8—lung cancer	0.000493	0.00288	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.00049	0.00286	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—lung cancer	0.000484	0.00282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—POMC—lung cancer	0.000483	0.00282	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—APP—lung cancer	0.000479	0.0028	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SKI—lung cancer	0.000477	0.00279	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3CA—lung cancer	0.00047	0.00274	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—lung cancer	0.000457	0.00267	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	0.00042	0.00245	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PXN—lung cancer	0.000415	0.00242	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AVP—lung cancer	0.00041	0.0024	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRP—lung cancer	0.000406	0.00237	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKR1C1—lung cancer	0.000406	0.00237	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—OXTR—lung cancer	0.000406	0.00237	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	0.000389	0.00227	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GNG11—lung cancer	0.00038	0.00222	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—lung cancer	0.000373	0.00218	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AVP—lung cancer	0.000373	0.00217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	0.000372	0.00217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFC—lung cancer	0.000362	0.00211	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADCY1—lung cancer	0.000342	0.00199	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PPP2R1B—lung cancer	0.000333	0.00194	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SMARCA4—lung cancer	0.000333	0.00194	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HSPB1—lung cancer	0.000321	0.00187	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTHLH—lung cancer	0.000318	0.00185	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ANXA1—lung cancer	0.000299	0.00174	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FLT1—lung cancer	0.000289	0.00169	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CG—lung cancer	0.000286	0.00167	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APP—lung cancer	0.000283	0.00165	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOTCH3—lung cancer	0.000283	0.00165	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF9—lung cancer	0.000281	0.00164	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—POMC—lung cancer	0.000273	0.00159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JUNB—lung cancer	0.000268	0.00156	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CG—lung cancer	0.00026	0.00152	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CD—lung cancer	0.000252	0.00147	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—POMC—lung cancer	0.000248	0.00145	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STK11—lung cancer	0.000243	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6R—lung cancer	0.000242	0.00141	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FOXO3—lung cancer	0.000235	0.00137	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAP2K1—lung cancer	0.00023	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CD—lung cancer	0.000229	0.00133	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AVP—lung cancer	0.00022	0.00128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CB—lung cancer	0.00022	0.00128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1R—lung cancer	0.000212	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—lung cancer	0.000211	0.00123	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HES1—lung cancer	0.000208	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RAF1—lung cancer	0.000204	0.00119	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2—lung cancer	0.000202	0.00118	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CB—lung cancer	0.000199	0.00116	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—lung cancer	0.000192	0.00112	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB3—lung cancer	0.00019	0.00111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2—lung cancer	0.000183	0.00107	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TERT—lung cancer	0.000182	0.00106	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGFR1—lung cancer	0.000177	0.00103	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIF1A—lung cancer	0.000174	0.00102	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOA1—lung cancer	0.000168	0.000983	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KDR—lung cancer	0.000167	0.000974	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CG—lung cancer	0.000154	0.000897	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KIT—lung cancer	0.000154	0.000897	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APC—lung cancer	0.000154	0.000897	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—NRAS—lung cancer	0.000154	0.000897	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGF—lung cancer	0.000152	0.000887	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK3—lung cancer	0.000147	0.000859	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—POMC—lung cancer	0.000146	0.000854	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BRAF—lung cancer	0.000144	0.000843	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6R—lung cancer	0.000143	0.000833	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CREBBP—lung cancer	0.000142	0.000832	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—lung cancer	0.00014	0.000817	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAP2K1—lung cancer	0.000136	0.000794	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CD—lung cancer	0.000135	0.000789	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CA—lung cancer	0.000134	0.000781	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KRAS—lung cancer	0.000132	0.000772	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CA—lung cancer	0.000122	0.000709	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MDM2—lung cancer	0.000121	0.000706	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RAF1—lung cancer	0.000121	0.000704	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB2—lung cancer	0.000119	0.000696	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MTOR—lung cancer	0.000118	0.000687	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CB—lung cancer	0.000118	0.000687	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—lung cancer	0.000113	0.00066	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRAS—lung cancer	0.000112	0.000656	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—lung cancer	0.000109	0.000638	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP3—lung cancer	0.000108	0.000632	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2—lung cancer	0.000108	0.000631	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—lung cancer	0.000108	0.000628	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCND1—lung cancer	0.000105	0.000615	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JUN—lung cancer	0.000105	0.000614	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—lung cancer	0.000102	0.000597	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1A—lung cancer	0.000102	0.000595	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTEN—lung cancer	0.000102	0.000594	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—lung cancer	9.93e-05	0.000579	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EP300—lung cancer	9.7e-05	0.000566	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SRC—lung cancer	9.44e-05	0.000551	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—lung cancer	9.19e-05	0.000536	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—lung cancer	9.1e-05	0.000531	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NRAS—lung cancer	9.08e-05	0.00053	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK3—lung cancer	8.69e-05	0.000507	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—lung cancer	8.46e-05	0.000494	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—lung cancer	8.27e-05	0.000483	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KRAS—lung cancer	7.81e-05	0.000456	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CA—lung cancer	7.18e-05	0.000419	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—lung cancer	6.94e-05	0.000405	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRAS—lung cancer	6.64e-05	0.000388	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—lung cancer	6.36e-05	0.000371	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—lung cancer	5.86e-05	0.000342	CbGpPWpGaD
